CD4 News and Research

RSS

Immune dysfunction persists after combined TB and HIV therapy

The immune system remains seriously out-of-whack – in an inflammatory state of overactivation and impaired functionality – following the international gold standard for treating people with latent tuberculosis (TB) and HIV, a team at Texas Biomedical Research Institute reports in Nature Communications.

14 Jan 2026

Aston Sci. Inc. implements CDD Vault to support AI-driven cancer vaccine development

Aston Sci. Inc., a clinical-stage biopharmaceutical company pioneering next-generation therapeutic cancer vaccines, announced today that it has implemented CDD Vault®, the secure, cloud-based research informatics platform from Collaborative Drug Discovery (CDD).

From Collaborative Drug Discovery, Inc. 10 Jan 2026

UBC researchers crack code to grow helper t cells from stem cells

For the first time, researchers at the University of British Columbia have demonstrated how to reliably produce an important type of human immune cell-known as helper T cells-from stem cells in a controlled laboratory setting.

8 Jan 2026

Soft wireless bioelectronic implant targets the splenic nerve to reduce inflammation

For millions suffering from chronic inflammatory diseases like inflammatory bowel disease (IBD), managing flare-ups often involves powerful drugs with significant side effects.

1 Jan 2026

Polysaccharide functionalized carbon dot nanovaccine boosts antitumor T cell responses

Recent advancements in cancer vaccine development have demonstrated their potential for precise tumor targeting through antigen-specific immune activation.

23 Dec 2025

Engineered extracellular vesicles enable antigen-specific regulatory T cell induction

A research team at the Nano Life Science Institute (WPI-NanoLSI) and the Faculty of Medicine at Kanazawa University has developed a new class of engineered extracellular vesicles (EVs) capable of inducing antigen-specific regulatory T cells (Tregs), the immune cells that play a central role in suppressing excessive immune responses.

22 Dec 2025

Chemotherapy may reduce HIV-infected T cells

Advancements in HIV/AIDS research, drug development and clinical practice since the 1980s have made it possible for people living with HIV to lead long, productive lives and keep the virus in check at undetectable levels and nontransmissible as long as therapy is maintained.

15 Dec 2025

Unnecessary gluten-free diets may put children at risk

Understanding gluten-related disorders is crucial for pediatric nutrition, as gluten-free diets can pose health risks without appropriate medical supervision.

15 Dec 2025

New findings show why the human intestine uniquely presents gluten to T cells

Human intestinal M cells function as dendritic cell-like antigen-presenting cells, displaying constitutive MHC-II activity and specialized machinery for processing gluten. Their ability to deamidate and present gliadin peptides positions them as key initiators of immune responses relevant to coeliac disease.

11 Dec 2025

Review highlights emerging role of tumor MHC-II in shaping cancer immunotherapy outcomes

Cancer immunotherapy has transformed cancer treatment, yet many patients experience limited or short-lived responses due to immune evasion, tumor heterogeneity, and immune-related adverse events.

11 Dec 2025

Poor dietary iron weakens lung memory T cells after flu infection

Dietary iron deficiency in mice alters lung T cell activation during influenza infection and leads to memory T cells that are present in normal or increased numbers but have impaired antiviral cytokine responses. These functional deficits are most pronounced in lung CD8-positive memory T cells and persist even under optimal recall conditions.

8 Dec 2025

Serious side effects after CAR T cell therapy for multiple myeloma share a common immune root cause

Serious side effects, including neurotoxicity and intestinal inflammation, that appear weeks or months after patients receive CAR T cell therapy for multiple myeloma share a common immune root cause, are associated with high rates of death unrelated to cancer relapse-primarily infection-and may be avoidable.

8 Dec 2025

Single-cell RNA sequencing uncovers diverse CD4⁺ T-cell subtypes in pediatric lupus

Detailed mapping of CD4⁺ T cells from children with systemic lupus erythematosus (SLE) has revealed distinct immune cell subsets with likely roles in disease pathogenesis, according to a study led by Weill Cornell Medicine investigators.

24 Nov 2025

Kimchi consumption strengthens antigen recognition and immune regulation

Amid concerns about the simultaneous spread of multiple respiratory diseases, such as colds and influenza, with the change of seasons in current times, a recent clinical study has scientifically proven that kimchi, a traditional Korean fermented food, enhances the function of human immune cells and maintains the balance of the immune system.

24 Nov 2025

New clues in pancreas lymph nodes, spleen could help detect and prevent type 1 diabetes

Type 1 diabetes (T1D) impacts nearly two million Americans, and by the time most people learn they have it, most of the body's insulin-producing cells are destroyed.

22 Nov 2025

Enhancing the cancer-immunity cycle through innovative vaccines

Therapeutic cancer vaccines have experienced a remarkable resurgence over the past decade, representing a paradigm shift in oncology toward harnessing the immune system's intrinsic ability to combat malignancies.

14 Nov 2025

Research identifies factors for long-term myeloma remission

A new study from the Icahn School of Medicine at Mount Sinai helps explain why some people with multiple myeloma, a type of blood cancer, stay in remission for many years after receiving CAR T cell therapy, while others see their cancer return sooner.

13 Nov 2025

Age and flu vaccine type influence immune activation

New research comparing four different flu vaccines found that the ability of the vaccines to activate cells of the immune system that help to protect against infection varied greatly depending on the vaccine type and age of the patient.

12 Nov 2025

Breakthrough research offers first targeted treatment option for NRAS-mutant melanoma

New research from Moffitt Cancer Center shows that RAS(ON) multi-selective inhibition can directly block tumor growth and activate the immune system, offering the first targeted approach for patients with NRAS-mutant melanoma, an aggressive form of skin cancer with limited treatment options beyond immune checkpoint inhibitors.

4 Nov 2025

Urolithin A recharges aging immune cells and boosts mitochondrial fitness in midlife adults

Urolithin A, a natural postbiotic known to trigger mitophagy, rejuvenated key immune cell functions in healthy middle-aged adults after 28 days. The trial showed a shift toward a youthful, energy-efficient CD8⁺ T-cell profile and enhanced bacterial clearance without inflammatory side effects.

3 Nov 2025